Peter Lawson
Stock Analyst at Barclays
(1.34)
# 3,552
Out of 4,964 analysts
98
Total ratings
38.82%
Success rate
-12.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SDGR Schrödinger | Initiates: Overweight | $25 | $19.79 | +26.33% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $5.53 | -45.75% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $38.51 | +3.87% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.72 | +74.42% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.12 | +78.57% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.06 | +670.52% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $7.81 | +28.04% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $2.42 | +65.29% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $8.02 | -25.14% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $7.86 | +39.95% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $8.08 | +98.02% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $6.99 | +114.59% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $10.56 | +32.58% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.86 | +61.29% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.87 | +60.43% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.41 | +183.69% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $38.04 | +57.73% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.57 | +376.19% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $16.26 | +102.95% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $32.65 | +102.14% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $9.55 | +224.61% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $6.90 | +88.41% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.28 | +290.63% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $2.07 | +69.08% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $99.54 | +266.69% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $39.27 | +17.14% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $29.28 | +1,436.89% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.67 | +1,585.39% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $53.53 | -15.93% | 2 | Jan 23, 2018 |
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $19.79
Upside: +26.33%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $5.53
Upside: -45.75%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $38.51
Upside: +3.87%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.72
Upside: +74.42%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.12
Upside: +78.57%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.06
Upside: +670.52%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $7.81
Upside: +28.04%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.42
Upside: +65.29%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $8.02
Upside: -25.14%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $7.86
Upside: +39.95%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $8.08
Upside: +98.02%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $6.99
Upside: +114.59%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $10.56
Upside: +32.58%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.86
Upside: +61.29%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.87
Upside: +60.43%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.41
Upside: +183.69%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $38.04
Upside: +57.73%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.57
Upside: +376.19%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $16.26
Upside: +102.95%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $32.65
Upside: +102.14%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $9.55
Upside: +224.61%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $6.90
Upside: +88.41%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.28
Upside: +290.63%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.07
Upside: +69.08%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $99.54
Upside: +266.69%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $39.27
Upside: +17.14%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $29.28
Upside: +1,436.89%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.67
Upside: +1,585.39%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $53.53
Upside: -15.93%